Observational studies on prevention of poor gestational outcome in carriers of thrombophilia
Patients, n . | Type of thrombophilia . | Obstetric history . | Treatment . | Live birth with normal outcome . | Reference no. . |
|---|---|---|---|---|---|
| 50 | Inherited and acquired | RFL | Enoxaparin (+ LDA for APS) | 46/61 (75%) | Brenner et al38 |
| 25 | Factor V Leiden or Factor II 20210G>A | RFL, preeclampsia IUGR | UFH or LMWH or LDA | 29/31 (93%) | Grandone et al39 |
| 33 | Not specified | Pregnancy complications | 40 mg enoxaparin + LDA | 30/33 (91%) | Kupferminc et al50 |
| 26 patients vs 19 controls | Inherited and acquired | Pregnancy complications | 40 mg enoxaparin + LDA | Higher birth weight in LMWH group | Riyazi et al40 |
| 37 patients vs 48 controls | Inherited | RFL | 40 mg enoxaparin | 70% vs 44% in controls | Carp et al41 |
Patients, n . | Type of thrombophilia . | Obstetric history . | Treatment . | Live birth with normal outcome . | Reference no. . |
|---|---|---|---|---|---|
| 50 | Inherited and acquired | RFL | Enoxaparin (+ LDA for APS) | 46/61 (75%) | Brenner et al38 |
| 25 | Factor V Leiden or Factor II 20210G>A | RFL, preeclampsia IUGR | UFH or LMWH or LDA | 29/31 (93%) | Grandone et al39 |
| 33 | Not specified | Pregnancy complications | 40 mg enoxaparin + LDA | 30/33 (91%) | Kupferminc et al50 |
| 26 patients vs 19 controls | Inherited and acquired | Pregnancy complications | 40 mg enoxaparin + LDA | Higher birth weight in LMWH group | Riyazi et al40 |
| 37 patients vs 48 controls | Inherited | RFL | 40 mg enoxaparin | 70% vs 44% in controls | Carp et al41 |
APS indicates antiphospholipid syndrome; LDA, low-dose aspirin; RFL, recurrent fetal loss; and IUGR, intrauterine growth restriction.